AtriCure, Inc. (ATRC) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

participants are in listen-only mode. We will be facilitating a question-and-answer session following the prepared remarks by HHR's management. I would now like to turn the call over to Marisa Beisch from the Gilmartin Group for a few introductory comments. Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call 513-644-7000. to have one emailed to you. Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond HRCUR's control, including risks and uncertainties described from time to time in HRCUR's SEC filings. These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for Atricure's franchises and growth initiatives, future product approvals and clearances, competition, reimbursement, and clinical trial outcomes. Atricure's results may differ materially from those projected. Atricure undertakes no obligation to publicly update any forward-looking statement. Additionally, we refer to non-GAAP financial measures. specifically constant currency revenue, adjusted EBITDA, and adjusted loss per share. A reconciliation of these non-GAAP financial measures with the most directly comparable GAAP measures is included in our press release, which is available on our website. With that, I would like to turn the call over to Mike Carroll, President and Chief Executive Officer. Good afternoon, and thank you for joining us. We are pleased to report an outstanding second quarter with total revenue of $136 million, reflecting a 17% year-over-year increase. Our growth was broad-based, rei...